Enzian’s history

Enzian Pharmaceutics has emerged from the doctoral thesis of Dr. Aron H. Blaesi, which started in 2009 at the Massachusetts Institute of Technology (MIT). Dr. Blaesi was counseled by Dr. Nannaji Saka, also an MIT alumnus. A timeline of Enzian’s history is shown below.

Aron Blaesi and Nannaji Saka

Dr. Aron Blaesi and Dr. Nannaji Saka developing an equation for calculating the drug concentration in gastric fluid after administering their dosage form.

2009

  • Dr. Blaesi was accepted to the PhD program in Mechanical Engineering at MIT.

  • He started working towards his PhD.

2010

  • Dr. Blaesi joined the Novartis-MIT Center for Continuous Manufacturing.

  • His work focused on the design of new machines and processes for continuous manufacture of pharmaceutical solid dosage forms (tablets).

2012

  • Dr. Blaesi and Dr. Saka met for the first time.

  • They started to collaborate on the design of new immediate-release dosage forms that could be economically manufactured.

  • Dr. Blaesi left the Novartis-MIT Center for Continous Manufacturing to work on independent research with Dr. Saka.

2014

  • First patent was filed on Polymeric cellular dosage forms for immediate drug release.

  • Dr. Blaesi graduated from MIT and joined the laboratory of the late Dr. Warren M. Zapol at the Massachusetts General Hospital, Harvard Medical School, to work on production and delivery of nitric oxide to the lungs.

  • Dr. Blaesi and Dr. Saka continued to do independent research on immediate-release dosage forms for economical manufacture.

2015

  • First patent was filed on dosage forms comprising three-dimensional structural frameworks.

  • First paper was published on Polymeric cellular dosage forms for immediate drug release.

2016

  • Enzian Pharmaceutics was incorporated as a collective society in Switzerland.

  • Dr. Blaesi left the Massachusetts General Hospital to work on independent research with Dr. Saka.

  • First patent was filed on fibrous dosage forms for immediate drug release.

2017

  • Enzian Pharmaceutics was incorporated as a C-corporation in Delaware.

  • First paper was published on fibrous dosage forms for immediate drug release.

  • Expandable fibrous dosage forms for prolonged drug delivery were discovered.

2018

  • First patent was filed on Expandable fibrous dosage forms.

  • Expandable fibrous dosage forms with strengthening excipient for prolonged drug delivery were discovered.

2020

  • First patent was filed and first paper was published on Expandable fibrous dosage forms with strengthening excipient.

  • Enzian Pharmaceutics was incorporated as a corporation (Aktiengesellschaft) in Switzerland.

  • Expandable fibrous dosage forms with strenghtening coating were discovered.

  • Prolonged gastric residence by expandable fibrous dosage forms with strenghtening coating was demonstrated for the first time in dogs.

2021

  • Prolonged gastric residence by expandable fibrous dosage forms with strenghtening coating was demonstrated for the first time in pigs.

2022

  • Expandable fibrous dosage forms with strenghtening excipient-coated fibers and drug-containing inter-fiber space for prolonged drug delivery were discovered.

  • The concept was validated on dogs for the first time using the tyrosine kinase inhibitor nilotinib as drug.

2023

  • First patent on expandable fibrous dosage forms with strenghtening excipient-coated fibers and drug-containing inter-fiber space was filed.

  • Prolonged gastric residence by expandable fibrous dosage forms was demonstrated for the first time in humans.

2024

  • The design, theoretical modeling, and experimental validation of gastroretentive fibrous dosage forms for prolonged delivery of sparingly-soluble tyrosine kinase inhibitors was published as a four-paper series.